Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer.

Background: There are several well-established environmental risk factors for ovarian cancer, and recent genome-wide association studies have also identified six variants that influence disease risk. However, the interplay between such risk factors and susceptibility loci has not been studied. Methods: Data from 14 ovarian cancer case–control studies were pooled, and stratified analyses by each environmental risk factor with tests for heterogeneity were conducted to determine the presence of interactions for all histologic subtypes. A genetic “risk score” was created to consider the effects of all six variants simultaneously. A multivariate model was fit to examine the association between all environmental risk factors and genetic risk score on ovarian cancer risk. Results: Among 7,374 controls and 5,566 cases, there was no statistical evidence of interaction between the six SNPs or genetic risk score and the environmental risk factors on ovarian cancer risk. In a main effects model, women in the highest genetic risk score quartile had a 65% increased risk of ovarian cancer compared with women in the lowest [95% confidence interval (CI), 1.48–1.84]. Analyses by histologic subtype yielded risk differences across subtype for endometriosis (Phet < 0.001), parity (Phet < 0.01), and tubal ligation (Phet = 0.041). Conclusions: The lack of interactions suggests that a multiplicative model is the best fit for these data. Under such a model, we provide a robust estimate of the effect of each risk factor that sets the stage for absolute risk prediction modeling that considers both environmental and genetic risk factors. Further research into the observed differences in risk across histologic subtype is warranted. Cancer Epidemiol Biomarkers Prev; 22(5); 880–90. ©2013 AACR.

Harvey Risch | Malcolm C Pike | Georgia Chenevix-Trench | Argyrios Ziogas | Jolanta Lissowska | Stefan Nickels | Hoda Anton-Culver | Jenny Chang-Claude | Daniel O Stram | Ellen L Goode | Brooke L Fridley | Montserrat Garcia-Closas | Nicolas Wentzensen | Susanne K Kjaer | Weiva Sieh | Rachel Palmieri Weber | Usha Menon | Aleksandra Gentry-Maharaj | Valerie McGuire | Rebecca Hein | Joellen M Schildkraut | Celeste Leigh Pearce | A. Whittemore | L. Kiemeney | M. Pike | R. Vierkant | J. Chang-Claude | M. García-Closas | B. Fridley | E. Goode | A. Berchuck | E. Iversen | P. Pharoah | D. Stram | A. Ziogas | H. Anton-Culver | U. Menon | A. Gentry-Maharaj | K. Aben | G. Chenevix-Trench | L. Brinton | J. Lissowska | J. Cunningham | M. Goodman | S. Kjaer | R. Hein | S. Nickels | A. Wu | S. Gayther | N. Wentzensen | R. Ness | H. Risch | R. Weber | J. Doherty | J. Schildkraut | K. Moysich | P. Moorman | L. Massuger | A. V. van Altena | C. Pearce | M. Carney | V. McGuire | W. Sieh | M. Rossing | P. Webb | A. Jensen | G. Lurie | E. Høgdall | S. Ramus | P. Thompson | Alice W. Lee | K. Terry | D. Stram | Andrew Berchuck | Leon F A G Massuger | Marc T Goodman | Paul Pharoah | Julie M Cunningham | Penelope M Webb | Susan J Ramus | Estrid Hogdall | Simon A Gayther | Anna H Wu | Jennifer A Doherty | Mary Anne Rossing | Galina Lurie | Patricia G Moorman | Louise Brinton | Robert A Vierkant | Michael E Carney | Pamela J Thompson | Kathryn L Terry | Allan Jensen | Lambertus A L M Kiemeney | Roberta B Ness | Katja K H Aben | Kirsten Moysich | Edwin Iversen | Alice W Lee | Susan M Jordan | Douglas A Stram | Anne M Van Altena | Alice Whittemore | S. M. Jordan | Daniel O. Stram | Douglas A. Stram | R. P. Weber | A. van Altena | A. Wu

[1]  R. Sankila,et al.  Cancer incidence in the first-degree relatives of ovarian cancer patients. , 1996, British Journal of Cancer.

[2]  Mark Sherman,et al.  Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. , 2009, Cancer research.

[3]  L. Sobin,et al.  Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. , 2003, American journal of epidemiology.

[4]  A. Whittemore,et al.  Histologic types of epithelial ovarian cancer: have they different risk factors? , 2005, Gynecologic oncology.

[5]  References , 1971 .

[6]  F. Nezhat,et al.  Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial , 2011 .

[7]  A. Whittemore,et al.  A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 , 2009, Nature Genetics.

[8]  D. Seminara,et al.  Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  David N. Rider,et al.  Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis , 2009, British Journal of Cancer.

[10]  R. Ness,et al.  Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. , 2011, Annals of epidemiology.

[11]  T. Stijnen,et al.  Review: a gentle introduction to imputation of missing values. , 2006, Journal of clinical epidemiology.

[12]  B. Thomsen,et al.  Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. , 2004, Archives of internal medicine.

[13]  M. Pike,et al.  Markers of inflammation and risk of ovarian cancer in Los Angeles County , 2009, International journal of cancer.

[14]  P. Hartge,et al.  Ovarian cancer risk factors by histologic subtypes in the NIH‐AARP diet and health study , 2012, International journal of cancer.

[15]  David V Conti,et al.  Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. , 2011, Human molecular genetics.

[16]  N. Weiss,et al.  Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery , 2008, Cancer Causes & Control.

[17]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[18]  A. Whittemore,et al.  Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. , 2004, American journal of epidemiology.

[19]  A. Berchuck,et al.  Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. , 2008, American journal of epidemiology.

[20]  C. la Vecchia,et al.  Risk factors for different histological types of ovarian cancer , 2003, International Journal of Gynecologic Cancer.

[21]  A. Green,et al.  Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer , 2008, International journal of cancer.

[22]  H. Risch,et al.  Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. , 1996, American journal of epidemiology.

[23]  D. Easton,et al.  Risk prediction models for familial breast cancer. , 2006, Future oncology.

[24]  P. Dickman,et al.  Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. , 2002, American journal of epidemiology.

[25]  M. Widschwendter,et al.  Tubal ligation and the risk of ovarian cancer: review and meta-analysis. , 2011, Human reproduction update.

[26]  L. Wilkens,et al.  Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk , 2010, Cancer Causes & Control.

[27]  V. Beral,et al.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls , 2008, The Lancet.

[28]  P. Hartge,et al.  Multiple births and risk of epithelial ovarian cancer. , 2000, Journal of the National Cancer Institute.

[29]  M. Pike,et al.  Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. , 2004, Fertility and sterility.

[30]  U. G. Dailey Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[31]  J. Chang-Claude,et al.  Low‐dose oral contraceptives: Protective effect on ovarian cancer risk , 2001, International journal of cancer.

[32]  A. Whittemore,et al.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 , 2010, Nature Genetics.

[33]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[34]  J. Gohagan,et al.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.

[35]  Matthew Burnell,et al.  Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. , 2011, Journal of clinical epidemiology.

[36]  C. la Vecchia,et al.  Risk factors for ovarian cancer histotypes. , 2007, European journal of cancer.